title: Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
abstract: The results of a randomized, double-blind, placebo-controlled multicenter trial of fenofibrate in the treatment of type IV/V hyperlipoproteinemia are reported. Ten study centers in the United States recruited 147 adults with a history of type IV or V hyperlipoproteinemia. After a six- to 12-week dietary stabilization period and a four-week placebo period, patients whose 12-hour fasting total plasma triglyceride levels ranged from 350 to 1,500 mg/dl were continued in the study; 55 patients with levels of 350 to 499 mg/dl were placed in group A and 92 with levels of 500 to 1,500 mg/dl in group B. Patients in each group were randomly assigned to receive 100 mg of fenofibrate or placebo three times daily for eight weeks. In both groups A and B fenofibrate-treated patients showed statistically significant reductions in levels of total cholesterol, very-low-density lipoprotein cholesterol, total triglycerides, and very-low-density lipoprotein triglycerides, and significant increases in high-density lipoprotein cholesterol; patients in group B also showed a significant increase in low-density lipoprotein cholesterol levels. Sixteen of the 75 fenofibrate-treated patients and 11 of the 72 placebo patients reported adverse events that were potentially drug related; most of these were gastrointestinal and a few reported musculoskeletal and skin reactions. It is concluded that fenofibrate is an effective and safe agent in the treatment of type IV/V hyperlipoproteinemia.
authors.affiliation: Washington University, St. Louis, Missouri.
authors.forename: A C
authors.initials: AC
authors.lastname: Goldberg
authors.forename: G
authors.initials: G
authors.lastname: Schonfeld
authors.forename: E B
authors.initials: EB
authors.lastname: Feldman
authors.forename: H N
authors.initials: HN
authors.lastname: Ginsberg
authors.forename: D B
authors.initials: DB
authors.lastname: Hunninghake
authors.forename: W
authors.initials: W
authors.lastname: Insull
authors.forename: R H
authors.initials: RH
authors.lastname: Knopp
authors.forename: P O
authors.initials: PO
authors.lastname: Kwiterovich
authors.forename: M J
authors.initials: MJ
authors.lastname: Mellies
authors.forename: J
authors.initials: J
authors.lastname: Pickering
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D006954:Hyperlipoproteinemia Type V / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*; D011897:Random Allocation; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014481:United States
chemical_list: D011422:Propionates; D014280:Triglycerides; D002784:Cholesterol; D011345:Fenofibrate